{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T11:28:48Z","timestamp":1782818928630,"version":"3.54.5"},"reference-count":86,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","progcardvascdis.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.pcad.2016.07.009","type":"journal-article","created":{"date-parts":[[2016,8,4]],"date-time":"2016-08-04T23:45:56Z","timestamp":1470354356000},"page":"153-164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Statin Intolerance: A Literature Review and Management Strategies"],"prefix":"10.1016","volume":"59","author":[{"given":"David R.","family":"Saxon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Eckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25 Suppl. 2","key":"10.1016\/j.pcad.2016.07.009_bb0005","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.pcad.2016.07.009_bb0010","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1056\/NEJMoa1315665","article-title":"Application of new cholesterol guidelines to a population-based sample","volume":"370","author":"Pencina","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.pcad.2016.07.009_bb0015","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ejim.2010.03.015","article-title":"The tolerability and efficacy of low-dose simvastatin in statin-intolerant patients","volume":"21","author":"Degreef","year":"2010","journal-title":"Eur J Intern Med"},{"issue":"3","key":"10.1016\/j.pcad.2016.07.009_bb0020","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/j.jacl.2014.03.002","article-title":"An assessment by the statin intolerance panel: 2014 update","volume":"8","author":"Guyton","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"23","key":"10.1016\/j.pcad.2016.07.009_bb0025","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","article-title":"Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial","volume":"308","author":"Sullivan","year":"2012","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.pcad.2016.07.009_bb0030","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2016.07.009_bb0035","article-title":"Clinical profile of statin intolerance in the phase 3 GAUSS-2 study","volume":"2","author":"Cho","year":"2016","journal-title":"Cardiovasc Drugs Ther Spons Int Soc Cardiovasc Pharmacother"},{"key":"10.1016\/j.pcad.2016.07.009_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/aoms.2015.49807","article-title":"Position paper statin intolerance \u2014 an attempt at a unified definition. Position paper from an International Lipid Expert Panel","volume":"1","author":"Banach","year":"2015","journal-title":"Arch Med Sci"},{"issue":"9753","key":"10.1016\/j.pcad.2016.07.009_bb0045","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet Lond Engl"},{"issue":"6","key":"10.1016\/j.pcad.2016.07.009_bb0050","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients \u2014the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"issue":"3","key":"10.1016\/j.pcad.2016.07.009_bb0055","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2012.03.003","article-title":"Understanding statin use in America and gaps in patient education (USAGE): an internet-based survey of 10,138 current and former statin users","volume":"6","author":"Cohen","year":"2012","journal-title":"J Clin Lipidol"},{"issue":"7","key":"10.1016\/j.pcad.2016.07.009_bb0060","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","article-title":"Discontinuation of statins in routine care settings: a cohort study","volume":"158","author":"Zhang","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pcad.2016.07.009_bb0065","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.atherosclerosis.2015.12.015","article-title":"Identification and management of patients with statin-associated symptoms in clinical practice: a clinician survey","volume":"245","author":"Hovingh","year":"2016","journal-title":"Atherosclerosis"},{"issue":"9326","key":"10.1016\/j.pcad.2016.07.009_bb0070","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF heart protection study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.pcad.2016.07.009_bb0075","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1161\/CIRCULATIONAHA.106.624890","article-title":"Risks associated with statin therapy: a systematic overview of randomized clinical trials","volume":"114","author":"Kashani","year":"2006","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.pcad.2016.07.009_bb0080","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ahj.2014.03.019","article-title":"A systematic review of statin-induced muscle problems in clinical trials","volume":"168","author":"Ganga","year":"2014","journal-title":"Am Heart J"},{"issue":"3","key":"10.1016\/j.pcad.2016.07.009_bb0085","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jacl.2014.03.004","article-title":"An assessment by the statin muscle safety task force: 2014 update","volume":"8","author":"Rosenson","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"3","key":"10.1016\/j.pcad.2016.07.009_bb0090","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0735-1097(02)02030-2","article-title":"ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins","volume":"40","author":"Pasternak","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.pcad.2016.07.009_bb0095","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.cjca.2013.09.023","article-title":"Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian working group consensus update","volume":"29","author":"Mancini","year":"2013","journal-title":"Can J Cardiol"},{"issue":"17","key":"10.1016\/j.pcad.2016.07.009_bb0100","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy\u2014European Atherosclerosis Society consensus panel statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.pcad.2016.07.009_bb0105","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/clpt.2014.121","article-title":"Phenotype standardization for statin-induced myotoxicity","volume":"96","author":"Alfirevic","year":"2014","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.pcad.2016.07.009_bb0110","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/MOL.0000000000000149","article-title":"Classification of reported statin intolerance","volume":"26","author":"Preiss","year":"2015","journal-title":"Curr Opin Lipidol"},{"issue":"6","key":"10.1016\/j.pcad.2016.07.009_bb0115","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.pcad.2016.07.009_bb0120","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.atherosclerosis.2011.11.005","article-title":"Statins as a possible cause of inflammatory and necrotizing myopathies","volume":"222","author":"Padala","year":"2012","journal-title":"Atherosclerosis"},{"issue":"7","key":"10.1016\/j.pcad.2016.07.009_bb0125","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMra1515161","article-title":"Statin-associated autoimmune myopathy","volume":"374","author":"Mammen","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.pcad.2016.07.009_bb0130","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme a reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"17","key":"10.1016\/j.pcad.2016.07.009_bb0135","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1056\/NEJMc1509640","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.pcad.2016.07.009_bb0140","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/MOL.0b013e32833c1edf","article-title":"The effects of statins on skeletal muscle strength and exercise performance","volume":"21","author":"Krishnan","year":"2010","journal-title":"Curr Opin Lipidol"},{"issue":"1","key":"10.1016\/j.pcad.2016.07.009_bb0145","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","article-title":"Effect of statins on skeletal muscle function","volume":"127","author":"Parker","year":"2013","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.pcad.2016.07.009_bb0150","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/bcp.12360","article-title":"Mechanisms and assessment of statin-related muscular adverse effects","volume":"78","author":"Mo\u00dfhammer","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.pcad.2016.07.009_bb0155","doi-asserted-by":"crossref","first-page":"858","DOI":"10.7326\/0003-4819-150-12-200906160-00009","article-title":"Narrative review: statin-related myopathy","volume":"150","author":"Joy","year":"2009","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.pcad.2016.07.009_bb0160","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1194\/jlr.M600301-JLR200","article-title":"Effects of lipoprotein lipase and statins on cholesterol uptake into heart and skeletal muscle","volume":"48","author":"Yokoyama","year":"2007","journal-title":"J Lipid Res"},{"issue":"4","key":"10.1016\/j.pcad.2016.07.009_bb0165","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00131402-200206000-00002","article-title":"Myopathy associated with HMG-CoA reductase inhibitors (statins): a series of 10 patients and review of the literature","volume":"3","author":"McKelvie","year":"2002","journal-title":"J Clin Neuromuscul Dis"},{"issue":"11","key":"10.1016\/j.pcad.2016.07.009_bb0170","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1001\/archneur.62.11.1709","article-title":"Muscle coenzyme Q10 level in statin-related myopathy","volume":"62","author":"Lamperti","year":"2005","journal-title":"Arch Neurol"},{"issue":"7","key":"10.1016\/j.pcad.2016.07.009_bb0175","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7326\/0003-4819-137-7-200210010-00009","article-title":"Statin-associated myopathy with normal creatine kinase levels","volume":"137","author":"Phillips","year":"2002","journal-title":"Ann Intern Med"},{"issue":"1\u20132","key":"10.1016\/j.pcad.2016.07.009_bb0180","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jns.2012.12.023","article-title":"Decreased skeletal muscle mitochondrial DNA in patients with statin-induced myopathy","volume":"325","author":"Stringer","year":"2013","journal-title":"J Neurol Sci"},{"issue":"suppl 2","key":"10.1016\/j.pcad.2016.07.009_bb0185","doi-asserted-by":"crossref","first-page":"S325","DOI":"10.2337\/dcS13-2038","article-title":"Intolerance to statins: mechanisms and management","volume":"36","author":"Bitzur","year":"2013","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.pcad.2016.07.009_bb0190","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy\u2014a genomewide study","volume":"359","author":"Link","year":"2008","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.pcad.2016.07.009_bb0195","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/MOL.0b013e3283168ecd","article-title":"Effects of ubiquinone (coenzyme Q10) on myopathy in statin users","volume":"19","author":"Schaars","year":"2008","journal-title":"Curr Opin Lipidol"},{"issue":"1","key":"10.1016\/j.pcad.2016.07.009_bb0200","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clpt.2005.03.006","article-title":"High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial","volume":"78","author":"P\u00e4iv\u00e4","year":"2005","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.pcad.2016.07.009_bb0205","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.mayocp.2014.08.021","article-title":"Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials","volume":"90","author":"Banach","year":"2015","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.pcad.2016.07.009_bb0210","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.atherosclerosis.2014.12.016","article-title":"A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy","volume":"238","author":"Taylor","year":"2015","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.pcad.2016.07.009_bb0215","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jacl.2011.06.013","article-title":"3-Hydroxyl-3-methylglutaryl coenzyme a reductase inhibitor use in chronic liver disease: a therapeutic controversy","volume":"5","author":"Tzefos","year":"2011","journal-title":"J Clin Lipidol"},{"issue":"2","key":"10.1016\/j.pcad.2016.07.009_bb0230","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jhep.2011.07.023","article-title":"Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing","volume":"56","author":"Bj\u00f6rnsson","year":"2012","journal-title":"J Hepatol"},{"issue":"suppl 3","key":"10.1016\/j.pcad.2016.07.009_bb0235","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jacl.2014.02.011","article-title":"An assessment by the statin liver safety task force: 2014 update","volume":"8","author":"Bays","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"4","key":"10.1016\/j.pcad.2016.07.009_bb0240","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.amjopharm.2012.05.002","article-title":"FDA drug safety communications: a narrative review and clinical considerations for older adults","volume":"10","author":"Marcum","year":"2012","journal-title":"Am J Geriatr Pharmacother"},{"issue":"3","key":"10.1016\/j.pcad.2016.07.009_bb0245","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s11606-014-3115-3","article-title":"Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials","volume":"30","author":"Ott","year":"2015","journal-title":"J Gen Intern Med"},{"issue":"9716","key":"10.1016\/j.pcad.2016.07.009_bb0250","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"issue":"9841","key":"10.1016\/j.pcad.2016.07.009_bb0255","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(12)61190-8","article-title":"Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial","volume":"380","author":"Ridker","year":"2012","journal-title":"Lancet"},{"issue":"suppl 3","key":"10.1016\/j.pcad.2016.07.009_bb0260","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.jacl.2014.02.012","article-title":"An assessment by the statin diabetes safety task force: 2014 update","volume":"8","author":"Maki","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"10","key":"10.1016\/j.pcad.2016.07.009_bb0265","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/j.amjcard.2014.02.011","article-title":"Effect of change in body weight on incident diabetes mellitus in patients with stable coronary artery disease treated with atorvastatin (from the treating to new targets study)","volume":"113","author":"Ong","year":"2014","journal-title":"Am J Cardiol"},{"issue":"8","key":"10.1016\/j.pcad.2016.07.009_bb0270","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/j.amjcard.2006.02.030","article-title":"Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force","volume":"97","author":"McKenney","year":"2006","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.pcad.2016.07.009_bb0275","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cjca.2012.11.032","article-title":"2012 Update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult","volume":"29","author":"Anderson","year":"2013","journal-title":"Can J Cardiol"},{"issue":"2","key":"10.1016\/j.pcad.2016.07.009_bb0280","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.metabol.2008.09.019","article-title":"Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia?","volume":"58","author":"Glueck","year":"2009","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.pcad.2016.07.009_bb0285","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1378\/chest.12-2016","article-title":"Rhabdomyolysis","volume":"144","author":"Zimmerman","year":"2013","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.pcad.2016.07.009_bb0290","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1345\/aph.1A289","article-title":"FDA adverse event reports on statin-associated rhabdomyolysis","volume":"36","author":"Omar","year":"2002","journal-title":"Ann Pharmacother"},{"issue":"4","key":"10.1016\/j.pcad.2016.07.009_bb0295","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/CRD.0b013e31817532db","article-title":"Statin\u2013drug interactions: not a class effect","volume":"16","author":"Frishman","year":"2008","journal-title":"Cardiol Rev"},{"issue":"10","key":"10.1016\/j.pcad.2016.07.009_bb0300","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0026-0495(97)90218-3","article-title":"Lovastatin increases exercise-induced skeletal muscle injury","volume":"46","author":"Thompson","year":"1997","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.pcad.2016.07.009_bb0305","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.amjcard.2011.08.045","article-title":"Effect of statins on creatine kinase levels before and after a marathon run","volume":"109","author":"Parker","year":"2012","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.pcad.2016.07.009_bb0310","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1152\/japplphysiol.00654.2015","article-title":"Influence of statins on distinct circulating microRNAs during prolonged aerobic exercise","volume":"120","author":"Min","year":"2016","journal-title":"J Appl Physiol"},{"issue":"10","key":"10.1016\/j.pcad.2016.07.009_bb0315","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.mayocp.2015.08.014","article-title":"Impact of statins on physical activity and fitness: ally or adversary?","volume":"90","author":"Franklin","year":"2015","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"10.1016\/j.pcad.2016.07.009_bb0320","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.mayocp.2015.06.019","article-title":"Effects of statin therapy on exercise levels in participants in the National Runners' and Walkers' Health Study","volume":"90","author":"Williams","year":"2015","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"10.1016\/j.pcad.2016.07.009_bb0325","first-page":"429","article-title":"The interaction between statins and exercise: mechanisms and strategies to counter the musculoskeletal side effects of this combination therapy","volume":"15","author":"Deichmann","year":"2015","journal-title":"Ochsner J"},{"issue":"1","key":"10.1016\/j.pcad.2016.07.009_bb0330","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.atherosclerosis.2014.11.012","article-title":"Vitamin D status modifies the association between statin use and musculoskeletal pain: a population based study","volume":"238","author":"Morioka","year":"2015","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.pcad.2016.07.009_bb0335","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.trsl.2008.11.002","article-title":"Low serum 25 (OH) vitamin D levels (<32ng\/mL) are associated with reversible myositis-myalgia in statin-treated patients","volume":"153","author":"Ahmed","year":"2009","journal-title":"Transl Res"},{"issue":"7","key":"10.1016\/j.pcad.2016.07.009_bb0340","first-page":"339","article-title":"Statin intolerance and vitamin D supplementation","volume":"7","author":"Khayznikov","year":"2015","journal-title":"N Am J Med Sci"},{"issue":"4","key":"10.1016\/j.pcad.2016.07.009_bb0345","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jacl.2014.05.005","article-title":"Hypothyroidism as a risk factor for statin intolerance","volume":"8","author":"Robison","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"13","key":"10.1016\/j.pcad.2016.07.009_bb0350","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","article-title":"Statin-associated myopathy","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.pcad.2016.07.009_bb0355","doi-asserted-by":"crossref","first-page":"614","DOI":"10.7326\/L14-5020-6","article-title":"Giant cell arteritis and polymyalgia rheumatica after reexposure to a statin: a case report","volume":"161","author":"de Jong","year":"2014","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.pcad.2016.07.009_bb0360","doi-asserted-by":"crossref","first-page":"e41289","DOI":"10.1371\/journal.pone.0041289","article-title":"Statin-associated polymyalgia rheumatica. An analysis using WHO global individual case safety database: a case\/non-case approach","volume":"7","author":"de Jong","year":"2012","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.pcad.2016.07.009_bb0365","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacl.2015.03.005","article-title":"Successful reintroduction of statin therapy after statin-associated rhabdomyolysis","volume":"9","author":"Simons","year":"2015","journal-title":"J Clin Lipidol"},{"issue":"2","key":"10.1016\/j.pcad.2016.07.009_bb0370","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s11883-014-0475-4","article-title":"Non-traditional dosing of statins in statin-intolerant patients\u2014is it worth a try?","volume":"17","author":"Cornier","year":"2015","journal-title":"Curr Atheroscler Rep"},{"issue":"2","key":"10.1016\/j.pcad.2016.07.009_bb0375","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.amjcard.2009.08.672","article-title":"Tolerability of red yeast rice (2,400mg twice daily) versus pravastatin (20mg twice daily) in patients with previous statin intolerance","volume":"105","author":"Halbert","year":"2010","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.pcad.2016.07.009_bb0380","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/jcpt.12374","article-title":"Systematic review of red yeast rice compared with simvastatin in dyslipidaemia","volume":"41","author":"Ong","year":"2016","journal-title":"J Clin Pharm Ther"},{"issue":"12","key":"10.1016\/j.pcad.2016.07.009_bb0385","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.amjcard.2015.09.023","article-title":"Usefulness of nutraceuticals (Armolipid plus) versus ezetimibe and combination in statin-intolerant patients with dyslipidemia with coronary heart disease","volume":"116","author":"Marazzi","year":"2015","journal-title":"Am J Cardiol"},{"issue":"15","key":"10.1016\/j.pcad.2016.07.009_bb0390","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jama.2016.3670","article-title":"PCSK9 inhibitors for statin intolerance?","volume":"315","author":"Waters","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2016.07.009_bb0395","author":"Food and Drug Administration Center for Drug Evaluation and Research"},{"issue":"25","key":"10.1016\/j.pcad.2016.07.009_bb0400","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.pcad.2016.07.009_bb0405","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"AIM-HIGH Investigators","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.pcad.2016.07.009_bb0410","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.pcad.2016.07.009_bb0415","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.pcad.2016.07.009_bb0420","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"issue":"9500","key":"10.1016\/j.pcad.2016.07.009_bb0425","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.pcad.2016.07.009_bb0430","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1177\/0091270010366446","article-title":"Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin","volume":"51","author":"Whitfield","year":"2011","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.pcad.2016.07.009_bb0435","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1001\/jama.288.4.455","article-title":"Long-term persistence in use of statin therapy in elderly patients","volume":"288","author":"Benner","year":"2002","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.pcad.2016.07.009_bb0440","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/HCO.0b013e32832ed62d","article-title":"Medication adherence and the patient with coronary artery disease: challenges for the practitioner","volume":"24","author":"Maddox","year":"2009","journal-title":"Curr Opin Cardiol"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062016300731?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062016300731?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,9]],"date-time":"2018-09-09T12:27:45Z","timestamp":1536496065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062016300731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0033062016300731"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2016.07.009","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Statin Intolerance: A Literature Review and Management Strategies","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2016.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}